These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25949875)

  • 1. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
    Li J; Chen QY; He J; Li ZL; Tang XF; Chen SP; Xie CM; Li YQ; Huang LX; Ye SB; Ke M; Tang LQ; Liu H; Zhang L; Guo SS; Xia JC; Zhang XS; Zheng LM; Guo X; Qian CN; Mai HQ; Zeng YX
    Oncoimmunology; 2015 Feb; 4(2):e976507. PubMed ID: 25949875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.
    Liang YJ; Chen QY; Xu JX; Liu XF; Xia JC; Liu LT; Guo SS; Song B; Wang P; Li JB; Liu Q; Mo HY; Guo L; Sun R; Luo DH; He J; Liu YN; Nie CP; Tang LQ; Li J; Mai HQ
    Eur J Cancer; 2023 Sep; 191():112965. PubMed ID: 37540921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal dynamics of tumor-infiltrating T-cell receptor beta-chain repertoires in the peripheral blood in response to concurrent chemoradiotherapy for Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Chung YL; Wu ML
    Oncoimmunology; 2021; 10(1):1968172. PubMed ID: 34513316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
    He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
    Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
    Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
    Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
    Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
    Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
    Louis CU; Straathof K; Bollard CM; Ennamuri S; Gerken C; Lopez TT; Huls MH; Sheehan A; Wu MF; Liu H; Gee A; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
    J Immunother; 2010; 33(9):983-90. PubMed ID: 20948438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
    Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
    Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.
    Toh HC; Yang MH; Wang HM; Hsieh CY; Chitapanarux I; Ho KF; Hong RL; Ang MK; Colevas AD; Sirachainan E; Lertbutsayanukul C; Ho GF; Nadler E; Algazi A; Lulla P; Wirth LJ; Wirasorn K; Liu YC; Ang SF; Low SHJ; Tho LM; Hasbullah HH; Brenner MK; Wang WW; Ong WS; Tan SH; Horak I; Ding C; Myo A; Samol J
    Ann Oncol; 2024 Sep; ():. PubMed ID: 39241963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
    Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
    Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
    J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up.
    Si Y; Deng Z; Lan G; Du H; Wang Y; Si J; Wei J; Weng J; Qin Y; Huang B; Yang Y; Qin Y
    Chem Pharm Bull (Tokyo); 2016; 64(8):1118-23. PubMed ID: 27477649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
    Lee AZE; Tan LSY; Lim CM
    Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.
    Lin MC; Lin YC; Chen ST; Young TH; Lou PJ
    BMC Cancer; 2017 Jan; 17(1):18. PubMed ID: 28056887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy.
    Li J; Zeng XH; Mo HY; Rolén U; Gao YF; Zhang XS; Chen QY; Zhang L; Zeng MS; Li MZ; Huang WL; Wang XN; Zeng YX; Masucci MG
    PLoS One; 2007 Nov; 2(11):e1122. PubMed ID: 17987110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.